Stock Markets November 16, 2026 08:01 PM

Gedeon Richter to Buy Mayne Pharma for A$604 Million; Mayne Shares Rally Sharply

Deal values Mayne at A$6.40 per share and lifts stock after unanimous board backing, pending approvals and completion of a prior asset sale

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
MYX

Hungary's Gedeon Richter has agreed to acquire Australian drugmaker Mayne Pharma for A$604 million (US$407 million) under a scheme implementation deed that prices Mayne at A$6.40 per share. The announcement sent Mayne stock sharply higher, and the transaction is subject to regulatory, shareholder and court approvals as well as the closing of a previously announced divestment of Mayne's international business to Evaris Pharma.

Gedeon Richter to Buy Mayne Pharma for A$604 Million; Mayne Shares Rally Sharply
MYX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Deal values Mayne at A$604 million (A$6.40 per share), a 99.4% premium to the November 16 closing price.
  • Mayne shares surged as much as 86.3% to A$5.98; Richter will fund the acquisition from internal cash.
  • The transaction impacts the pharmaceutical and healthcare sectors, strengthening Richter's US presence, particularly in women's health.

Deal overview

Gedeon Richter PLC has reached an agreement to acquire Mayne Pharma for A$604 million, or A$6.40 in cash per Mayne share, the companies said on Tuesday. The A$6.40 cash consideration equals a 99.4% premium to Mayne's closing share price on November 16 and values the transaction at roughly US$407 million.

Market reaction

Sydney-listed Mayne shares jumped sharply after the announcement, rising as much as 86.3% to A$5.98 by 00:51 GMT. That intraday move took the stock to its highest level since Nov, 2025.

Board recommendation and conditions

Mayne's board has unanimously recommended that shareholders vote in favour of the transaction, provided there is no superior proposal and subject to an independent expert concluding the deal is in the best interests of shareholders. The scheme is conditional on a number of approvals and actions, meaning completion is not guaranteed.

Financing and regulatory steps

Richter said the acquisition will be fully funded from its internal cash resources. The deal remains subject to regulatory approvals, shareholder and court approvals, and the completion of Mayne Pharma's previously announced sale of its international business to Evaris Pharma.

Timeline

The shareholder vote is expected to take place in late January 2027, and the companies are targeting completion of the transaction in March.

Strategic rationale cited by Richter

Richter indicated the acquisition would bolster its footprint in the United States, with particular emphasis on women's health and other therapeutic areas where Mayne has operations.


Clear summary

Gedeon Richter has agreed to buy Mayne Pharma for A$604 million - A$6.40 per share in cash - a bid that values Mayne at roughly US$407 million and represents a near-doubling premium to a mid-November closing price. The Mayne board supports the deal pending an independent expert opinion and in the absence of a better offer. Completion depends on regulatory, shareholder and court approvals and Mayne's divestment of its international business to Evaris Pharma. A shareholder vote is expected in late January 2027 with closing targeted for March.

Key points

  • Acquisition price: A$604 million total consideration, A$6.40 per share in cash, a 99.4% premium to the November 16 close.
  • Market impact: Mayne shares rose as much as 86.3% to A$5.98, the highest since Nov, 2025; Richter said it will fund the purchase from internal cash.
  • Sector and market implications: The transaction affects the pharmaceutical and healthcare sectors, with implications for US women's health exposure and Australian equity markets.

Risks and uncertainties

  • The deal is contingent on regulatory approvals, shareholder and court approvals, meaning it could be delayed or fail to complete.
  • Completion also depends on Mayne finalising the previously announced sale of its international business to Evaris Pharma.
  • Mayne's board recommendation is conditional - it is subject to no superior proposal emerging and to an independent expert determining the transaction is in shareholders' best interests.

Risks

  • The transaction is conditional on regulatory, shareholder and court approvals and could be delayed or fail to complete - affects pharmaceutical markets and investor sentiment.
  • Completion is contingent on Mayne finalising the sale of its international business to Evaris Pharma - impacts corporate restructuring and M&A timelines.
  • Mayne's board recommendation is subject to no superior proposal and an independent expert finding the deal is in shareholders' best interests - introduces uncertainty for shareholders and potential competing bids.

More from Stock Markets

Panama to Enter Talks with Minera Panama on Potential Cobre Panama Restart Nov 16, 2026 Strategy Inc Shares Drop After Bitcoin Slide, MSCI Delisting Threat Adds Pressure Nov 16, 2026 Taiwan market retreats as benchmark falls 5.74% at Monday close Nov 16, 2026 Volatility Reboots the Case for Hard Assets, UBS Says Nov 15, 2026 Newly Installed Router in Arkansas Overwhelms FAA Network, Triggers Nationwide Grounding Nov 15, 2026